p16/p14ARF cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease

Clinical Cancer Research

Volumn 7, Issue 11, 2001, Pages 3481-3490

  Omura Minamisawa, Motoko ^a   Diccianni, Mitchell B ^a   Chang, Ray C ^a   Batova, Ayse ^a   Bridgeman, Louis J ^a   Schiff, Jessica ^a   Yu, Alice L ^a   Cohn, Susan L ^b   London, Wendy B ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CELL CYCLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

CELL CYCLE; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MUTATION; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035187023     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Statistical estimation of prognosis for children with neuroblastoma
2. Neuroblastoma, its natural history and prognosis: A study of 487 cases
3. Spontaneous regression of neuroblastoma
4. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
5. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
6. Chromosomal aberrations in human neuroblastomas
7. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma
8. The p16 and p18 tumor suppressor genes in neuroblastoma: Implications for drug resistance
9. Low frequency of the p53 gene mutations in neuroblastoma
10. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification
11. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTSI/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas
12. Role of the cyclin-dependent kinase inhibitors in the development of cancer
13. Cancer cell cycles
14. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins
15. Identification of G1 kinase activity for cdk6, a novel cyclin D partner
16. The retinoblastoma protein binds to a family of E2F transcription factors
17. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
18. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
19. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
20. Germline p16 mutations in familial melanoma
21. Mutations and altered expression of p 161NK4 in human cancer
22. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining
23. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas
24. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2
25. A p18 mutant defective in CDK6 binding in human breast cancer cells
26. Germline mutations in the p161NK4a binding domain of CDK4 in familial melanoma
27. Retinoblastoma protein family in cell cycle and cancer: A review
28. The retinoblastoma protein and cell cycle control
29. Mutational analysis of the p16 gene in human neuroblastomas
30. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma
31. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma
32. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma
33. Frequent deregulation of p16 and the p 16/Gl cell cycle-regulatory pathway in neuroblastoma
34. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb
35. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4
36. A novel p16INK4A transcript
37. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
38. Complex structure and regulation of the p16 (MTS1) locus
39. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
40. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
41. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
42. Tumor surveillance via the ARF-p53 pathway
43. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer
44. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
45. Biological classification of cell lines derived from human extra-cranial neural tumors
46. Neuroblastoma: A multiple biological disease
47. Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas
48. The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients
49. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer
50. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavorable prognosis
51. p16 overexpression: A potential early indicator of transformation in ovarian carcinoma
52. Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein
53. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma
54. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer
55. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers
56. Enhanced expression of p16ink4a is associated with a poor prognosis in childhood acute lymphoblastic leukemia
57. Role of the retinoblastoma protein in the pathogenesis of human cancer
58. Cyclin-dependent kinase inhibitor p 16INK4A inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH
59. HTLV-1 tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4
60. Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms
61. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins
62. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins